Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:SRRK 23 August 2025 - 30 December 2025

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

Scholar Rock shares fell 3.2% to $43.76 Tuesday afternoon, underperforming biotech peers as investors watched for updates on FDA reinspection timing for its lead drug, apitegromab. The company aims to resubmit its biologics license application in 2026 after the Indiana fill-finish site, now owned by Novo Nordisk, completes remediation and is reinspected by year-end 2025.
30 December 2025
·
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock shares surged 26% to $37.98 after an FDA meeting on its SMA therapy and the launch of a $200 million at-the-market stock offering. The company reported a Q3 2025 net loss of $102.2 million, up from $64.5 million a year earlier, with no revenue as it prepares for a potential U.S. launch in 2026. Trading volume topped 2.7 million shares.
14 November 2025
····
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Electronic Arts shares jumped 15% after agreeing to a $55 billion buyout led by Saudi Arabia’s PIF, offering $210 per share. Crinetics Pharmaceuticals soared 28% as the FDA approved its oral acromegaly drug. QMMM Holdings surged 19% before the SEC halted trading over suspected manipulation. Scholar Rock gained 12% despite an FDA delay for its spinal atrophy drug.
29 September 2025
·····
Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

The FDA issued a Complete Response Letter for Scholar Rock’s apitegromab on Sept. 23, citing only manufacturing issues at a third-party Indiana plant. Shares fell but analysts, including BMO and Leerink, maintained bullish outlooks, expecting a quick resolution. The EMA review continues, with a possible EU launch in late 2026. Scholar Rock reported $295 million in cash as of June 30.
26 September 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······

Stock Market Today

  • Stocks Slip as US-Iran Ceasefire Optimism Wanes; Oil Prices Surge
    April 9, 2026, 12:18 PM EDT. Stocks dipped as S&P 500, Dow Jones, and Nasdaq 100 indexes retreated following fading optimism over a US-Iran ceasefire. June E-mini futures reflected this softening trend. Crude oil jumped over 5%, driven by the Strait of Hormuz blockade and escalating tensions from Israeli-Lebanon clashes, threatening the fragile truce. Both the US and Iran accused each other of ceasefire breaches, complicating Saturday's talks. U.S. economic data disappointed, with rising unemployment claims, weaker personal income and spending, and downwardly revised Q4 GDP growth adding pressure. Oil tanker restrictions amplified shipping delays, with over 1,000 vessels waiting near the strait, historically a key global energy transit route. Markets price in only a 2% chance of a Federal Reserve rate hike in late April, while overseas shares also fell, weighing on sentiment.

Latest article

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Go toTop